Buy or sell Inscripta stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Inscripta Stock
Inscripta is a gene editing technology company.
About Inscripta Stock
Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing. By removing the barriers to forward cell engineering and gene-editing research, Inscripta will usher in a new era of advances to revolutionize how we feed, fuel, and heal humanity. Inscripta is led by several genomic technology veterans including CEO Kevin Ness, who co-founded QuantaLife and 10x Genomics, and John Stuelpnagel, the chairman of the company's board, who was co-founder and first CEO of Illumina and chairman of 10x Genomics. Inscripta is headquartered in Boulder, Colo.; has offices in Pleasanton, Calif.; and is backed by Venrock, MLS Capital, NanoDimension, Foresite, Paladin Capital Group, and Mérieux Développement.
Investors
NanoDimension
Funding History
April 2016 | $6.0M |
---|---|
February 2017 | $23.1M |
February 2018 | $55.5M |
January 2019 | $50.0M |
November 2019 | $175M |
March 2021 | $150M |
Management
General Counsel
Dianna DeVore
VP Finance
Eric Warnecke
CSO & Founder
Ryan T Gill
VP Product Development
Michael Graige
VP Software
Todd Rubano
VP Biology
Paul Hardenbol
Executive Director of Data Science
Richard Fox
CEO
Kevin Ness
CTO, VP R&D, Co Founder
Tanya Lipscomb
VP Engineering
Don Masquelier
Press
Forbes - Dec, 13 2017
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase